Echinocandins are antifungal agents that specifically inhibit the biosynthesis of 1,3-β-D-glucan, a major structural component of fungal cell walls. Echinocandins are recommended as first-line or alternative/salvage therapy for candidiasis and aspergillosis in antifungal guidelines of various countries. Resistance to echinocandins has been reported in recent years. The mechanism of echinocandin resistance involves amino acid substitutions in hot spot regions of the FKS gene product, the catalytic subunit of 1, 3-β -D-glucan synthase. This resistance mechanism contributes to not only acquired resistance in Candida spp., but also inherent resistance in some pathogenic fungi. An understanding of the echinocandin resistance mechanism is important to develop both effective diagnosis and treatment options for echinocandin-resistant fungal diseases.
Introduction
The three echinocandins, namely, anidulafungin, caspofungin, and micafungin, are in widespread clinical use. Of these, caspofungin and micafungin are available in Japan. Echinocandins are exclusively indicated for treatment of Candida and Aspergillus infections because they show excellent antifungal activity against Candida spp. and Aspergillus spp. without cross-resistance to existing antifungal agents. They are less active, however, against Cryptococcus spp., Trichosporon spp., Fusarium spp., Scedosporium/Lomentospora spp., and Mucorales 1, 2) . Echinocandins have generally favorable safety and tolerability profiles with adequate pharmacokinetics and few drug interactions 1, 2) . Moreover, in recent years, a large amount of clinical evidence for echinocandins have been accumulated [3] [4] [5] [6] [7] [8] . In consequence, the Infectious Diseases Society of America (IDSA), the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), the Japanese Society for Medical Mycology (JSMM), and the Japanese Mycoses Forum (JMF) recommend echinocandins as initial therapy for invasive candidiasis in their clinical guidelines [9] [10] [11] [12] [13] [14] . In Japan, caspofungin and micafungin are also recommended as first-line therapy for chronic progressive pulmonary aspergillosis 8, 13, 15) . For the reasons mentioned above, the use of echinocandins for prophylaxis and treatment has been expanding, and more than 60% of candidemia patients are now reported to receive an echinocandin 16) . The incidence of echinocandin resistance has remained relatively low for a decade. However, as the application of echinocandins increased, clinical failures due to resistant organisms, especially Candida spp., are becoming more frequent 17) . Echinocandins exhibit their antifungal activity by inhibition of the fungal-specific enzyme 1,3-β-D-glucan synthase, a catalytic subunit of which is encoded by the FKS gene 18) . In this review, we will focus on the role of the FKS gene in various pathogenic fungi to explain their susceptibility or resistance (reduced susceptibility) to echinocandins.
Target of echinocandins: 1,3-β-D-glucan synthase
Echinocandins specifically and non-competitively inhibit the biosynthesis of 1,3-β-D-glucan, a major structural component of fungal cell walls 18, 19) . Echinocandins substantially show fungicidal activity against susceptible Candida spp. 20, 21) , and have killing activity against actively growing hyphae of Aspergillus spp., even though they are not fungicidal against the entire fungal burden 22, 23) . The 1, 3-β -D-glucan synthase comprises a catalytic subunit embedded in the plasma membrane and a regulatory subunit localized in the cytoplasm. In the baker's yeast Saccharomyces cerevisiae, the catalytic subunit is an approximately 215-kDa integral protein with 16 transmembrane helices 24) . The regulatory subunit is a small GTP-binding protein, Rho1 25) .
FKS gene encoding 1,3-β-D-glucan synthase catalytic subunit
In S. cerevisiae, mutations in FKS1 (for FK506 hypersensitive 1) conferred hypersensitivity to the immunosuppressants FK506 and cyclosporine A 24, 26) , both of which intrinsically show weak antifungal activity. On the other hand, mutations in the S. cerevisiae gene named ETG1 (for echinocandin target gene 1) gave resistance to echinocandins 27) . The FKS1 and ETG1 genes were found to be identical and to encode a catalytic subunit of 1, 3-β -D-glucan synthase 24) . In S. cerevisiae, three related FKS genes, FKS1, FKS2, and FKS3 have been cloned. Fks1 and Fks2 are highly homologous (88%) 28) , while Fks3 shares 56% identity with Fks1 and Fks2 29) . FKS1 is primarily expressed during vegetative growth, while FKS2 is mostly expressed during sporulation 28) . S. cerevisiae with disruption of either FKS1 or FKS2 is viable, but simultaneous disruption of FKS1 and FKS2 is lethal, suggesting that Fks1 and Fks2 are alternative subunits with essential overlapping functions 28) . FKS3 is also expressed during sporulation, but its expression level is very low relative to FKS1 and FKS2 29) . The orthologs of S. cerevisiae FKS genes have been cloned in various pathogenic fungi. Candida albicans and Candida glabrata have three FKS genes like S. cerevisiae, while Aspergillus fumigatus and Cryptococcus neoformans have a single FKS gene 18) . The FKS gene family encodes a~210 kDa protein, localizing within the plasma membrane with at most 16 transmembrane helices predicted by hydropathy analysis 18) .
FKS gene and susceptibility to echinocandins
Genetic studies with echinocandin analogs in S. cerevisiae 24, 27) and C. albicans 30, 31) indicated that Fks1 is the target of echinocandins. The modification of the target site reduced the sensitivity of 1,3-β-D-glucan synthase to echinocandins, causing decreased susceptibility of these organisms to echinocandins 27, 30, 31) . Mutations conferring reduced susceptibility in S. cerevisiae and C. albicans were mapped to FKS1 30, 31) . Inversely, mutations in FKS1 were confirmed to confer resistance following their introduction into a susceptible strain 32) . Amino acid substitutions associated with resistance defined two limited but highly conserved regions termed "hot spot 1 (HS1)" and "hot spot 2 (HS2)" of Fks1 in S. cerevisiae and various pathogenic fungi 32, 33) . HS1 encompasses Phe639-Pro647 in S. cerevisiae 24, 34) and Phe641-Pro649 in C. albicans 31, 35) (Table 1) , and HS2 includes Asp1353-Leu1360 in S. cerevisiae and Asp1357-Leu1364 in C. albicans 33) . Strains with acquired echinocandin resistance have mutations in the hot spot regions of FKS genes, while some of the inherently echinocandin-resistant fungal species, such as Candida parapsilosis 41) and Fusarium solani 50) , have naturally occurring polymorphisms in these regions.
FKS genes in pathogenic fungi
C. albicans has three FKS genes, FKS1, FKS2, and FKS3 35) . C. glabrata has also three FKS genes 36) . FKS1 is essential in C. albicans 31) and most other Candida spp., while simultaneous disruption of FKS1 and FKS2 is lethal in C. glabrata, meaning FKS1 and FKS2 are functionally redundant in C. glabrata 36) . FKS genes have been cloned and sequenced from various Candida spp., and amino acid sequences of HS1 in Fks1 have been predicted from them ( Table 1 ). The HS1 regions of Fks1 in C. glabrata 36) , Candida tropicalis 37) , Candida krusei 38) , Candida dubliniensis 39) , Candida lipolytica 40, 41) , Candida kefyr 42) , and Candida lusitaniae 43) share high homology with those of C. albicans. All of them are susceptible to echinocandins like C. albicans 56, 57) . The Candida parapsilosis complex (Candida parapsilosis sensu strict, Candida orthopsilosis, and Candida metapsilosis) have higher MIC values for echinocandins compared with other susceptible Candida spp. 41, 58) . The 1, 3-β -D-glucan synthase prepared from C. parapsilosis is 10-to 50-fold less sensitive to echinocandins relative to that from C. albicans 41) . C. parapsilosis complex has a naturally occurring polymorphism in HS1 of Fks1. In comparison with amino acid sequence of HS1 in C. albicans Fks1, Pro660 of HS1 in C. parapsilosis is substituted with alanine (P660A, equivalent to P649A in C. albicans) 41) . Engineering the P647A mutation into Fks1 of S. cerevisiae (equivalent to P660A in C. parapsilosis and P649A in C. albicans) resulted in mutants with remarkable decrease in sensitivity of 1,3-β-D-glucan synthase and increase in MICs for echinocandins 41) . It appears that one amino acid substitution in Fks1 of C. parapsilosis complex accounts for their intrinsically reduced susceptibility to echinocandins. Candida guilliermondii also has higher echinocandin MIC value like C. parapsilosis 56, 57) . C. guilliermondii harbors two amino acid polymorphisms in HS1 of Fks1, where Leu633 is substituted with methionine (L633M, equivalent to L642M in C. albicans) and Thr634 is substituted with alanine (T634A, equivalent to T643A in C. albicans) 36) . The engineered strains of S. cerevisiae, in which a region of FKS1 gene was replaced with that of C. guilliermondii, showed 32-fold increase in echinocandin MIC values 44) . The reduced echinocandin susceptibility of C. guilliermondii appears to be due to these naturally occurring substitutions.
Aspergillus spp.
Aspergillus nidulans 45) , Aspergillus fumigatus 46) , and Aspergillus lentulus (a cryptic species of A. fumigatus) 47) have been reported to have a single FKS gene (FKS1) to date. In comparison with amino acid sequence of HS1 in C. albicans Fks1, both A. nidulans 45) and A. fumigatus 46) have two amino acid substitutions in their HS1 (Table 1 ). In HS1 of A. nidulans Fks1, Leu675 is substituted with isoleucine (L675I, equivalent to L646I in C. albicans), and Arg676 is substituted with lysine (R676K, equivalent to R647K in C. albicans) 45, 48) . Likewise, in HS1 of A. fumigatus, Leu680 is substituted with phenylalanine (L680F, equivalent to L646F in C. albicans), and Arg681 is substituted with lysine (R681K, equivalent to R647K in C. albicans) 46, 48) . Amino acid sequence of HS1 in A. lentulus is the same as that in A. fumigatus 47) (Table 1) . A.
fumigatus, A. nidulans, and most other Aspergillus spp. are susceptible to echinocandins 56, 59) . However, A. lentulus isolates overall are less susceptible to caspofungin, although they are susceptible to anidulafungin and micafungin. These differential echinocandin susceptibilities in A. lentulus are considered to be independent of the polymorphisms of its Fks1 47) .
Cryptococcus spp.
Cryptococcus neoformans and Cryptococcus gattii are inherently resistant to echinocandins 60, 61) . Nevertheless, C. neoformans has a single FKS gene (FKS1) that is essential for viability despite a lower content of glucan in its cell wall 48) . In comparison with amino acid sequence of HS1 in C. albicans Fks1, Leu538 of HS1 in C. neoformans is substituted with phenylalanine (L538F, equivalent to L646F in C. albicans) 48) ( Table 1 ). The leucine-to-phenylalanine substitution at the homologous position (L644F) in S. cerevisiae Fks1 had no effect on the echinocandin sensitivity of either whole cells or enzyme activity 48) . Moreover, 1,3-β-D-glucan synthase activity from C. neoformans was very sensitive to caspofungin 62) .
These results indicate that the mechanism of inherent resistance of C. neoformans to echinocandins is not related to target enzyme insensitivity. Recently, the CDC50 gene encoding the β -subunit of lipid flippase, a protein that regulates the asymmetrical orientation of membrane lipids, was found to be responsible for C. neoformans resistance to caspofungin 63) . On the other hand, C. neoformans was sensitized to micafungin by introducing a mutation in some of the ERG genes encoding late ergosterol biosynthetic pathway enzymes. Addition of ergosterol to the culture of erg mutants recovered their resistance to micafungin 64) . However, for both cdc50 and erg mutants, sensitivity to echinocandins was only moderately increased, suggesting the presence of other factor(s) contributing to echinocandin resistance in C. neoformans. 4. Trichosporon spp.
Trichosporon spp. also show inherent resistance to echinocandins 56) , although the plasma β-D-glucan concentration is elevated in patients infected with them 65) . The amino acid sequence of HS1 in Trichosporon asahii Fks1 (GenBank database Accession No. JH925095) 49) is the same as that of C.
neoformans (Table 1) . Unfortunately, there is no available literature concerning Trichosporon spp. FKS gene. The mechanism of inherent resistance of Trichosporon spp. to echinocandins remains to be clarified. 5. Fusarium spp. Fusarium spp. are intrinsically resistant to echinocandins 56) . Fusarium solani has a single essential FKS gene (FKS1) 50) . In comparison with amino acid sequence of HS1 in C. albicans Fks1, F. solani has three amino acid substitutions in its HS1 51) ( Table 1 ). Phe683 is substituted with tyrosine (equivalent to F641Y in C. albicans), Thr685 with isoleucine (equivalent to T643I in C. albicans), and Leu688 with phenylalanine (equivalent to L646F in C. albicans) 51) . The equivalent substitutions of T685I and L688F in HS1 of F. solani Fks1 are found in echinocandin-susceptible C. glabrata and A. fumigatus, respectively, whereas the equivalent substitution of F683Y was implicated in the acquired echinocandin resistance of a C. albicans clinical isolate 36) . Replacement of A. fumigatus Fks1 with F. solani Fks1 caused a modest increase in the tolerance of A. fumigatus for caspofungin 50) . In addition, replacement of S. cerevisiae Fks1 with hybrid S. cerevisiae Fks1 incorporating F. solani HS1 (F639Y) resulted in significantly reduced echinocandin susceptibility 51) . These results indicate that the mechanism of inherent resistance of F. solani to echinocandins can be attributed to the amino acid substitution in HS1 of its Fks1.
Dematiaceous fungi
Lomentospora prolificans is intrinsically resistant to echinocandins 66) . L. prolificans has a single FKS gene (FKS1) 51) . In comparison with amino acid sequence of HS1 in C. albicans Fks1, L. prolificans has two amino acid substitutions in its HS1 51) (Table 1 ). Phenylalanine and leucine of HS1 in L. prolificans Fks1 (equivalent to Phe641 and Leu646 of HS1 in C. albicans Fks1, respectively) are substituted with tyrosine and phenylalanine, respectively 51) . Of these amino acid substitutions, F641Y (C. albicans equivalent), as mentioned regarding F. solani Fks1, is believed to contribute to the inherent resistance of L. prolificans to echinocandins. Besides, the W695F (S. cerevisiae equivalent) substitution in L. prolificans Fks1 has been reported to impart reduced echinocandin susceptibility, in the same way that this mutation in S. cerevisiae decreased its susceptibility to echinocandins 67) . Alternaria infectoria exhibits reduced susceptibility to caspofungin 52) . A. infectoria has a single FKS gene (FKS1) 52) . Amino acid sequence of HS1 in A. infectoria Fks1 is the same as that of A. nidulans 52) (Table 1 ). The mechanism of the inherently reduced susceptibility of A. infectoria to echinocandins is unclear.
Mucorales
Mucor spp., Rhizopus spp., Cunninghamella spp., and Absidia spp. are intrinsically resistant to echinocandins 56) . Rhizopus oryzae has a single FKS gene (FKS1) 68) . Nevertheless, caspofungin inhibited the activity of 1,3-β-D-glucan synthase from R. oryzae only at a high concentration and did not exhibit antifungal activity against this strain 68) . There is no data available for amino acid sequence of HS1 in R. oryzae Fks1. Considering the inhibitory activity of caspofungin against 1,3-β-D-glucan synthase, it is probable, but not certain, that amino acid substitution(s) in HS1 may be related to the inherent resistance of R. oryzae to echinocandins.
Dimorphic fungi
Micafungin exhibited potent antifungal activity against the mycelial form of Histoplasma capsulatum, Blastomyces dermatitidis, and Coccidioides immitis, while it was very weakly active against the yeast-like form of H. capsulatum and B. dermatitidis (C. immitis: not tested) 69) . Micafungin also showed moderate antifungal activity against the mycelial form of Paracoccidioides brasiliensis, Penicillium marneffei, and Sporothrix schenckii 69) , but little activity against their yeastlike form. The MICs of caspofungin against the mycelial form of H. capsulatum were also lower than those against its yeastlike form 70, 71) . In P. brasiliensis, one FKS gene (FKS1) and two DNA fragments related to FKS gene have been cloned 53) . The amino acid sequence of HS1 in P. brasiliensis Fks1 is the same as that of C. neoformans (Table 1) , wherein there is no polymorphism contributing to echinocandin resistance 53) . It has been reported that the cell wall of the yeast-like form of P. brasiliensis contains predominantly α-glucan and only small amounts of β -glucan, whereas β -glucan is abundant in the mycelial form 72) . Such is the case with H. capsulatum and B. dermatitidis 73, 74) . It thus appears reasonable that echinocandins Medical Mycology Journal Volume 59, Number 2, 2018 E 34 are active against the mycelial form but inactive against the yeast-like form of these dimorphic fungi. Coccidioides posadasii has a single essential FKS gene (FKS1) 54) . The amino acid sequence of HS1 in C. posadasii Fks1 is the same as that of A. nidulans (Table 1) , i. e., C. posadasii has no mutations to induce echinocandin resistance 54) . In C. posadasii, FKS1 is expressed during spherule development at levels similar to or slightly less than its levels in mycelia, but its expression levels decrease as spherules mature 54) . This may explain why the antifungal effect of cilofungin, an echinocandin analog, on C. immitis dramatically decreased with the development of spherule 75) .
Pneumocystis jirovecii
Pneumocystis jirovecii has a single FKS gene (FKS1) 55) . The amino acid sequence of HS1 in P. jirovecii Fks1 is almost the same as that of C. albicans, with the substitution of threonine by serine (T713S, equivalent to T643S in C. albicans) 55) ( Table 1 ). This replacement does not contribute to echinocandin resistance 55) . Echinocandins exhibited antifungal activity against P. jirovecii in suspension and biofilm cultures 76) , in animal models of infection 77, 78) , and in clinical practice 79, 80) . P. jirovecii has two forms, a trophozoite and a cyst, in its life cycle. High concentrations of 1,3-β-glucan were present in the P. jirovecii cyst wall, but 1,3-β-glucan was absent from intracystic bodies and trophozoites 81) . Considerable Fks1 was present in P. jirovecii cysts, while in contrast, detectable but rather limited amounts of Fks1 were observed in trophozoites 55) . Furthermore, the expression of FKS1 mRNA is regulated differently through the P. jirovecii life cycle, having substantial expression in cysts, but minimal expression in trophozoites 55) . The echinocandins thus act on cyst wall formation but not on trophozoite proliferation 78, 81) .
Acquired resistance to echinocandins by fks mutations
Resistance to echinocandins, since first reported in 2005 32) , remains relatively low (< 3%) in C. albicans and other Candida spp. 82) , but is rapidly increasing in C. glabrata 83, 84) . The SENTRY surveillance program (2006-2010) reported that 8.0-9.3% were resistant to echinocandins among 1,669 bloodstream isolates of C. glabrata 84) . Moreover, in a 10-year survey at Duke University Hospital, among 293 episodes (313 isolates) of C. glabrata bloodstream infection, resistance to echinocandins increased from 4.9% to 12.3% between 2001 and 2010 83) . Rapid emergence of resistance in C. glabrata has historically been ascribed to its haploid genome. Recently, it is reported that defects in mismatch repair represent a key underlying cellular mechanism that facilitates acquisition of resistance in C. glabrata 85) . Besides C. albicans and C. glabrata, acquired resistance has been reported in many Candida spp., such as C. tropicalis 86, 87) , C. krusei 32, 86) , C. dubliniensis 39, 88) , C. kefyr 42, 89) , and C. lusitaniae 43, 90) . The most frequent amino acid substitutions in Fks1 of C. albicans are S645F/P/Y (46%), followed by F641S/L (33%), R1361H (6%), multiple mutations (6%), L644Stop (3%), D648Y (3%), and P649H (3%) 91) . Of these, S645F/P/Y and F641S/L cause the most pronounced resistance [92] [93] [94] . In C. glabrata clinical isolates, resistance-related mutations occur in both FKS1 and FKS2, but the frequency of amino acid substitutions in Fks2 is twice that of Fks1 36, 93, 94) . The most prominent amino acid substitutions in C. glabrata are Ser663 in Fks2, Ser629 in Fks1, and Phe659 in Fks2 93) . In the study of patients with invasive candidiasis due to C. glabrata, the presence of an fks mutation was the only independent risk factor for failure of echinocandin therapy, and detection of C. glabrata fks mutations was superior to MICs in predicting echinocandin therapeutic responses among these patients 95) . Recently, an echinocandin-resistant A. fumigatus isolate (F675S in HS1 of Fks1) was recovered from a patient with chronic pulmonary aspergillosis 96) .
Conclusions and perspective
Pathogenic fungi can be divided into six types based on HS1 of their Fks and their susceptibility to echinocandins: (1) no mutations and susceptible, such as C. albicans and A. fumigatus, (2) with mutations and reduced susceptibility, such as C. parapsilosis and C. guilliermondii, (3) no mutations and susceptible in only one of two morphological forms, such as dimorphic fungi (mycelial-form) and P. jirovecii (cyst), (4) no information about HS1 and highly resistant, such as Rhizopus oryzae, (5) no mutations and highly resistant, such as C. neoformans and T. asahii, and (6) with mutations and highly resistant, such as F. solani, L. prolificans, and Candida spp. with acquired resistance.
For fungal infections by most of Candida spp. and Aspergillus spp. (type 1), echinocandins have been recommended as first-line or alternative/salvage therapy in various clinical guidelines 8-15, 97, 98) . Echinocandins demonstrate higher MIC levels against C. parapsilosis and C. guilliermondii (type 2) than most other Candida spp., which raises the concern that they may be less responsive to echinodandins. However, there have been no clinical studies that have demonstrated the inferiority of echinocandins compared to other antifungals for the treatment of C. parapsilosis infections 99) . For treatment of blastomycosis 100) , coccidioidomycosis 101) , and Pneumocystis pneumonia 79, 80) (type 3), though not approved nor recommended, it has been reported that echinocandins, alone or in combination, was effective. For therapy of mucormycosis (type 4), combination of lipid formulations of amphotericin B and echinocandins, though its mechanism is unknown, has often been used [102] [103] [104] and recommended as first-line or salvage therapy in some guidelines 97, 105) . Cryptococcus spp. and Trichosporon spp. (type 5) show inherent resistance to echinocandins by other mechanisms than point mutations of Fks 63, 64) . This indicates the possibility of combination therapy with echinocandins and an inhibitor of this unknown echinocandin-resistant mechanism. For F. solani, L. prolificans, and fungi with acquired resistance (type 6), novel echinocandins or chemical entities that inhibit mutant Fks/1,3β-D-glucan synthase are desirable 106, 107) since the fungalspecific 1,3-β-D-glucan synthase is an ideal molecular target for antifungal agents. A better understanding of the echinocandin resistance mechanism is critical to develop both effective diagnosis and treatment options for echinocandin-resistant fungal diseases.
